Discontinued drugs in 2011: Oncology drugs

Expert Opinion on Investigational Drugs

Volumn 22, Issue 1, 2013, Pages 9-34

  Williams, Robert ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

5 FU; AGS 16M18; AGS 8M4 ASP 6183; ALS 357; AMG 102; AMG 655; AMG 951; Amolimogene bepiplasmid; Amonafide malate; AS 1413; AZD 2461; AZD 4769; AZD 7762; AZD 8055; Betulinic acid; Biotope CD; Conatumumab; CVX 241; Dacetuzumab; Davanat 1; Dulanermin; EMD 1204831; Figitumumab; Goserelin; IMC EB10; IMGN 388; IPH 1101; MEDI 547; MGN 1706; OncoGel; PF 00562271; PF 03732010; PF 03758309; PF 04217903; PF 05057459; RG 7347; Rilotumumab; SGN 40; SSR 97225; TAK 285; TAK 901; Tenifatecan; TRX 518; XL 228; XL 888; Zalatumumab; ZYC 101a

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; AGS 16M18; AGS 8M4; AMOLIMOGENE BEPIPLASMID; AMONAFIDE; ANTINEOPLASTIC AGENT; ASP 6183; AZD 2461; AZD 4769; AZD 8055; BETULIC ACID; CONATUMUMAB; CVX 241; DACETUZUMAB; DTS 301; DULANERMIN; EMD 1204831; FIGITUMUMAB; FLUOROURACIL; GOSERELIN; IMC EB10; IMGN 388; IPH 1101; MEDI 547; MGN 1706; PACLITAXEL; PF 03072010; PF 03732010; PF 03758309; PF 04217903; PF 0421793; PF 0505459; PF 05057459; PF 0562271; PF 309; PF 3732010; PF 4217903; PF 562271; PRO 1762; PRO 64553; RG 3636; RG 7347; RILOTUMUMAB; SGN 14; SSR 97225; TAK 285; TAK 901; TENIFATECAN; TRX 518; UNCLASSIFIED DRUG; XL 228; XL 888; XLS 001; ZALUTUMUMAB; ZYC 00101;

ACUTE GRANULOCYTIC LEUKEMIA; BILE DUCT CANCER; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONTROLLED RELEASE FORMULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECALL; DRUG WITHDRAWAL; EWING SARCOMA; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; STOMACH CANCER; TREATMENT FAILURE; TREATMENT INDICATION; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 84871016117     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.739605     Document Type: Review

References (15)

1. Williams RJ. Discontinued drugs in 2010: oncology drugs. Expect Opin Investig drugs 2011;20(11) l479-9
2. Pammo Hi F, Magazzani L, Riccaboni M. The productivity crisis in pharmaceuticaI R&D. Nat Rev Drug Discov 2011;10(6):428-38
3. Kessel M. The poem with today's phamaceutical business-an outsider's view. Nat Biotech 2011;29(1)27-33
4. Scannell JW, Blanckley A, Bolden H, Waington B. Diagnosing the decline in phamaceutical R&D efficiency. Nat Rev Dug Discov 2012;11(3)191-200
5. Aowsmith J. A decade of change. Nat Rev Dug Discov 2012;11(1):17-18
6. Mulle A. 2011 in eflection. Nat Rev Dug Discov 2012;11(1):6-8
7. http://www.phma.og/tack-pdf.phpq=/sites/default/fìles/15 9/phma-industy-pofìle.pdf
8. Beggen R, Molle M, Moss R, et al. Outlook fo the next 5 yeas in dug innovation. Nat Rev Dug Discov 2012;11(6):435-6
9. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to impove R&D poductivity: the phamaceutical industy's gand challenge. Nat Rev Dug Discov 2010;9(3)203-14
10. Rubin EH, Gilland DG. Dug development and clinical tiaIs-the patl to an appoved cance dug. Nat Rev Clin Oncol 2012;9(4)215-22
11. CMR Intenational 2012 Phamaceutical R&D actbook
12. Yap TA, Sandhu SK, Wokman P, de Bono JS. Envisioning the future of ealy anticance dug development. Nat Rev Cance 2010;10(7)5l4-23
13. Yap TA, Wokman P. Exploiting the cance genome: stategies fo the discovey and development of tageted molecula theapeutics. Annu Rev Phamacol Toxicol 2012;52549-73
14. http://www.nice.og.uk/newsoom/pesseleases/ NICEConsultsOnNewTreatmentFoSkinCance.jsp
15. http://www.pmlive.com/phama-news/b io make-analysis-evives-fo tunes- of-amgens-ilotumumab-404048